Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. METHODS: In two randomized, placebo-controlled, phase 3 trials of identical design (SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe atopic dermatitis whose disease was inadequately controlled by topical treatment. Patients were randomly assigned in a 1:1:1 ratio to receive, for 16 weeks, subcutaneous dupilumab (300 mg) or placebo weekly or the same dose of dupilumab every other week alternating with placebo. The primary outcome was the proportion of patients who had both a score of 0 or 1 (clear or almost clear) on the Investigator's Global Assessment and a reduction of 2 points or more in that score from baseline at week 16. RESULTS: We enrolled 671 patients in SOLO 1 and 708 in SOLO 2. In SOLO 1, the primary outcome occurred in 85 patients (38%) who received dupilumab every other week and in 83 (37%) who received dupilumab weekly, as compared with 23 (10%) who received placebo (P<0.001 for both comparisons with placebo). The results were similar in SOLO 2, with the primary outcome occurring in 84 patients (36%) who received dupilumab every other week and in 87 (36%) who received dupilumab weekly, as compared with 20 (8%) who received placebo (P<0.001 for both comparisons). In addition, in the two trials, an improvement from baseline to week 16 of at least 75% on the Eczema Area and Severity Index was reported in significantly more patients who received each regimen of dupilumab than in patients who received placebo (P<0.001 for all comparisons). Dupilumab was also associated with improvement in other clinical end points, including reduction in pruritus and symptoms of anxiety or depression and improvement in quality of life. Injection-site reactions and conjunctivitis were more frequent in the dupilumab groups than in the placebo groups. CONCLUSIONS: In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo. Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743 ; SOLO 2 ClinicalTrials.gov number, NCT02277769 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As neurons express receptors for IL-4 and IL-13, the early improvement of itch upon targeted therapy with dupilumab, tralokinumab or lebrikizumab supports the assumption of a direct effect of these drugs on nerve endings92,96,183.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [183]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two phase 3 trials found dupilumab to significantly improve symptoms and quality of life in patients with AD compared to placebo [39].”
From Atopic dermatitis (2018) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Upadacitinib, a JAK inhibitor with proven efficacy in moderate-tosevere AD 30,31 , and dupilumab, an IL-4Rα antagonist that blocks IL-4/IL-13 signalling 32,33 , were selected.”
From Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Atopic dermatitis: a disease of altered skin barrier and immune dysregulation
Boguniewicz, M., & Leung, D. Y. M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01027.x · Cited by 1,073
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citation
Cited by
Items 401–500 of 1,002
Chiricozzi, A., Ortoncelli, M., Schena, D., Gori, N., Ferrucci, S. M., Babino, G., Napolitano, M., Fargnoli, M. C., Stingeni, L., Rossi, M., et al. (2023) · American Journal of Clinical Dermatology · doi:10.1007/s40257-023-00798-0 · Cited by 63
DUCA, E. D., He, H., Liu, Y., Pagan, A. D., David, E., Cheng, J., Carroll, B. E., Renert‐Yuval, Y., Bar, J., Estrada, Y. D., et al. (2023) · Allergy · doi:10.1111/all.15845 · Cited by 61
Self-citationImmune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
Seremet, T., Di Domizio, J., Girardin, A., Yatim, A., Jenelten, R., Messina, F., Saidoune, F., Schlapbach, C., Bogiatzi, S., Minisini, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54559-6 · Cited by 57
The Economics Burden of Atopic Dermatitis
Adamson, A. S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-64804-0_8 · Cited by 69
A case series of dupilumab-treated allergic contact dermatitis patients
Goldminz, A. M., & Scheinman, P. L. (2018) · Dermatologic Therapy · doi:10.1111/dth.12701 · Cited by 57
Pranzatelli, M. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00557 · Cited by 62
Jang, D. H., Heo, S., Jung, H. J., Park, M. Y., Seo, S. J., & Ahn, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061982 · Cited by 58
“The mean DLQI of our patients was higher than that of patients in previous clinical trials [3,13,14], because unlike in other countries, 42.”
ResultSilverberg, J. I., Hong, H., Thyssen, J. P., Calimlim, B., Joshi, A. D., Teixeira, H. D., Collins, E. B., Crowell, M. M., Johnson, S. J., & Armstrong, A. W. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00721-1 · Cited by 61
Self-citationCytokine modulation of atopic itch
Trier, A. M., & Kim, B. S. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.05.005 · Cited by 55
Touhouche, A. T., Cassagne, M., Bérard, E., Giordano‐Labadie, F., Didier, A. P., Fournié, P., Paul, C. F., & Tauber, M. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16724 · Cited by 59
Blauvelt, A., Ladizinski, B., Prajapati, V. H., Laquer, V. T., Fischer, A., Eisman, S., Hu, X., Wu, T., Calimlim, B., Kaplan, B., et al. (2023) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.05.033 · Cited by 60
Self-citationOptMAVEn-2.0: De novo Design of Variable Antibody Regions against Targeted Antigen Epitopes
Chowdhury, R., Allan, M. F., & Maranas, C. D. (2018) · Antibodies · doi:10.3390/antib7030023 · Cited by 55
“Antibodies are versatile molecules produced in B-cells and have become the basis of many therapeutics [1–3] and diagnostics [4–6] for cancers [6–8], infectious diseases [9], and autoimmune disorders [10].”
BackgroundUnderstanding the Burden of Atopic Dermatitis in Africa and the Middle East
Al-Afif, K. A., Buraik, M. A., Buddenkotte, J., Mounir, M., Gerber, R. A., Ahmed, H. M., Tallman, A. M., & Steinhoff, M. S. (2019) · Dermatology and Therapy · doi:10.1007/s13555-019-0285-2 · Cited by 63
The Challenge of Managing Atopic Dermatitis in the United States.
Feldman, S. R., Cox, L., Strowd, L. C., Gerber, R. A., Faulkner, S., Sierka, D., Smith, T. W., Cappelleri, J. C., & Levenberg, M. (2019) · PubMed · Cited by 61
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
Castro, M., Rabe, K. F., Corren, J., Pavord, I. D., Katelaris, C. H., Tohda, Y., Zhang, B., Rice, M. S., Maroni, J. M., Rowe, P., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00204-2019 · Cited by 57
Self-citationRecent advancements in the atopic dermatitis mechanism
Savva, M., Papadopoulos, N. G., Gregoriou, S., Katsarou, S., Papapostolou, N., Makris, M., & Xepapadaki, P. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2902084 · Cited by 53
“Subsequently, new therapeutic targets aiming at inhibiting IL-4R using monoclonal antibodies and JAK inhibitors are developed [137,138], while the inhibition of IL-13 using monoclonal antibodies attenuates the itch in AD [18,19].”
BackgroundAbraham, S., Haufe, E., Harder, I., Heratizadeh, A., Kleinheinz, A., Wollenberg, A., Weisshaar, E., Augustin, M., Wiemers, F., Zink, A., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18958 · Cited by 53
Self-citationMycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis
Phan, K. H., & Smith, S. D. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1642996 · Cited by 53
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases
Canonica, G. W., BOURDIN, A. A., Peters, A. T., Desrosiers, M. Y., Bachert, C., Weidinger, S., Simpson, E. L., Daizadeh, N. S., Chen, Z., Kamat, S., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.02.026 · Cited by 56
Self-citationAhmad, H. I., Jabbar, A., Mushtaq, N., Javed, Z., Hayyat, M. U., Bashir, J., Naseeb, I., Abideen, Z. U., Ahmad, N., & Chen, J. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.827407 · Cited by 74
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
Bansal, A., Simpson, E. L., Paller, A. S., Siegfried, E. C., Blauvelt, A., de Bruin-Weller, M., Corren, J., Sher, L., Guttman-Yassky, E., Chen, Z., et al. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00577-1 · Cited by 52
Self-citationDupilumab-Associated Ocular Surface Disease: Clinical Characteristics, Treatment, and Follow-Up
Bohner, A. D., Topham, C. A., Strunck, J. L., Haynes, D., Brazil, M., Clements, J. L., Simpson, E. L., & Chamberlain, W. (2020) · Cornea · doi:10.1097/ico.0000000000002461 · Cited by 53
Self-citationA pragmatic guide to choosing biologic therapies in severe asthma
Kavanagh, J. E., Hearn, A. P., & Jackson, D. J. (2021) · Breathe · doi:10.1183/20734735.0144-2021 · Cited by 64
“It was first licensed for use in atopic dermatitis [78, 79], but has subsequently demonstrated efficacy in severe eosinophilic asthma.”
BackgroundSindher, S., Nadeau, K. C., Chinthrajah, R. S., Leflein, J. G., Bégin, P., Ohayon, J., Ponda, P., Wambre, E. R., Liu, J., Khokhar, F. A., et al. (2024) · Allergy · doi:10.1111/all.16404 · Cited by 60
“…activity of IL-4 and IL-13 [22] and is currently approved for use by the US Food and Drug Administration in patients with the following type 2 inflammatory diseases: atopic dermatitis (AD), asthma, chronic rhinosi-nusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis [23–29].”
InfluentialSelf-citationEconomic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Kuznik, A., Bégo-Le-Bagousse, G., Eckert, L., Gadkari, A. S., Simpson, E. L., Graham, C. N., Miles, L., Mastey, V., Mahajan, P. S., & Sullivan, S. D. (2017) · Dermatology and Therapy · doi:10.1007/s13555-017-0201-6 · Cited by 53
Self-citationBiologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines
Boguniewicz, M. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.08.031 · Cited by 55
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP
Bachert, C., Zinreich, S. J., Hellings, P. W., Mullol, J., Hamilos, D. L., Gevaert, P., Naclerio, R. M., Amin, N., Joish, V. N., Fan, C., et al. (2019) · Rhinology Journal · doi:10.4193/rhin18.282 · Cited by 52
Self-citationTavecchio, S., Angileri, L., Giuffrida, F. P., Germiniasi, F., Marzano, A. V., & Ferrucci, S. M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092684 · Cited by 55
Solimando, A. G., Desantis, V., & Ribatti, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214004 · Cited by 62
Simpson, E. L., Silverberg, J. I., Worm, M., Honari, G., Masuda, K., Syguła, E., Schuttelaar, M. L. A., Mortensen, E. R., Laws, E., Akinlade, B. K., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.12.066 · Cited by 51
Self-citationDupilumab for the treatment of asthma
Pelaia, C., Vatrella, A., Gallelli, L., Terracciano, R., Navalesi, P., Maselli, R., & Pelaia, G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1387245 · Cited by 53
Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
Frampton, J. E., & Blair, H. A. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0370-9 · Cited by 55
Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab
Barroso-García, B., Rial, M. J., Molina, Á., & Sastre, J. (2018) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0301 · Cited by 53
Uchida, H., Kamata, M., Mizukawa, I., Watanabe, A., Agematsu, A., Nagata, M., Fukaya, S., Hayashi, K., Fukuyasu, A., Tanaka, T. L., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18163 · Cited by 51
Recent advances in mast cell activation and regulation
Kim, H. S., Kawakami, Y., Kasakura, K., & Kawakami, T. (2020) · F1000Research · doi:10.12688/f1000research.22037.1 · Cited by 55
Corneal fibroblasts: Function and markers
Fukuda, K. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108229 · Cited by 54
An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata
Glickman, J. W., Dubin, C., Dahabreh, D., Han, J., DUCA, E. D., Estrada, Y. D., Zhang, N., Kimmel, G. W., Singer, G., Krueger, J. G., et al. (2021) · Allergy · doi:10.1111/all.14814 · Cited by 52
Self-citationRoles of Mast Cells in Cutaneous Diseases
Numata, T., Harada, K., & Nakae, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923495 · Cited by 56
“org 6 inhibits binding of IL-4 and IL-13 to IL-4Ra improved the signs and symptoms of AD (including pruritus), anxiety and depression, as well as the quality of life, compared to placebo controls (82).”
BackgroundInnate type 2 immunity controls hair follicle commensalism by Demodex mites
Ricardo-González, R. R., Kotas, M. E., O’Leary, C. E., Singh, K., Damsky, W., Liao, C., Arouge, E., Tenvooren, I., Marquez, D. M., Schroeder, A., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.001 · Cited by 52
Neuroimmune interactions in atopic and allergic contact dermatitis
Liu, A. W., Gillis, J. E., Sumpter, T. L., & Kaplan, D. H. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.03.013 · Cited by 60
Spekhorst, L. S., Boesjes, C. M., Loman, L., Zuithoff, N. P. A., Bakker, D. S., Kamphuis, E., Kamsteeg, M., Haeck, I. M., Oosting, A. J., van Lümig, P. P. M., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad159 · Cited by 57
Wu, Y., Zhou, Z., Zhang, M., Li, S., Sun, M., & Song, Z. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02174-w · Cited by 58
“ROS signaling participates in promoting IL-4 secretion after Th2 cell activation, and Th2 cells play a crucial role in the pathogenesis of AD, mainly leading to an increase in IL-4 levels [29].”
BackgroundAtopic Dermatitis, Depression, and Suicidality
Nicholas, M. N., & Gooderham, M. (2017) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475416685078 · Cited by 57
Interactions of the immune and sensory nervous systems in atopy
Oetjen, L. K., & Kim, B. (2018) · FEBS Journal · doi:10.1111/febs.14465 · Cited by 55
Eosinophils Determine Dermal Thickening and Water Loss in an MC903 Model of Atopic Dermatitis
Naidoo, K., Jagot, F., van den Elsen, L. W. J., Pellefigues, C., Jones, A., Luo, H., Johnston, K. A., Painter, G. F., Roediger, B., Lee, J., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.06.168 · Cited by 58
“Dupilumab, a human monoclonal antibody to the alpha subunit of the IL-4 receptor (impairing the signaling of both IL-4 and IL-13) recently approved by the US Food and Drug Administration (Oh et al., 2010), has shown clinical benefit (Beck et al., 2014; Simpson et al., 2016), but only in a subset of patients.”
BackgroundMethodResultInfluentialHahn, M., & Ghoreschi, K. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1279054 · Cited by 50
“More recently, the monoclonal anti-IL-4Rα antibody dupilumab has been tested in the setting of atopic dermatitis with 40–50% of patients achieving >75% improvement in the eczema area and severity index [12].”
Mikhaylov, D., DUCA, E. D., Olesen, C. M., He, H., Wu, J., Ungar, B., Estrada, Y. D., Zhang, N., Chowdhury, M., Clausen, M., et al. (2021) · Dermatitis · doi:10.1097/der.0000000000000764 · Cited by 51
Self-citationMiyagawa, F. (2022) · Biomedicines · doi:10.3390/biomedicines10071485 · Cited by 54
“Multiple clinical trials have demonstrated the efficacy and safety of dupilumab against moderate-to-severe AD [91,92].”
BackgroundSpekhorst, L. S., de Graaf, M., Zuithoff, N. P. A., van den Reek, J. M. P. A., Kamsteeg, M., Boesjes, C. M., Romeijn, G. L. E., Loman, L., Haeck, I. M., Oosting, A. J., et al. (2022) · JAMA Dermatology · doi:10.1001/jamadermatol.2022.3014 · Cited by 49
Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis
Koskeridis, F., Εvangelou, Ε., Ntzani, E., Κostikas, Κ., & Tsabouri, S. (2022) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/12034754221130969 · Cited by 55
IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases
Lavazais, S., Jargosch, M., Dupont, S., Labéguère, F., Menet, C. J., Jagerschmidt, C., Ohm, F., Kupcsik, L., Parent, I., Cottereaux, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abj3289 · Cited by 51
Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review
Park, C. O., Kim, S. M., Lee, K. H., & Bieber, T. R. M. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105121 · Cited by 60
Self-citationDupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
Chinthrajah, R. S., Sindher, S., Nadeau, K. C., Leflein, J. G., Spergel, J. M., Petroni, D., Jones, S. M., Casale, T. B., Wang, J., Carr, W. W., et al. (2024) · Allergy · doi:10.1111/all.16420 · Cited by 56
Self-citationMolecular aspects of allergens in atopic dermatitis
Campana, R., Dzoro, S., Mittermann, I., Fedenko, E. S., Elisyutina, O. G., Khaitov, M. R., Karaulov, A. V., & Valenta, R. (2017) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000378 · Cited by 53
Ocular surface disease associated with dupilumab treatment for atopic diseases
Utine, C. A., Li, G., Asbell, P. A., Pflugfelder, S. C., & Akpek, E. K. (2020) · The Ocular Surface · doi:10.1016/j.jtos.2020.05.008 · Cited by 53
Badloe, F. M. S., Vriese, S. D., Coolens, K., Schmidt‐Weber, C. B., Ring, J., Gutermuth, J., & Krohn, I. K. (2020) · Clinical and Translational Allergy · doi:10.1186/s13601-020-00338-7 · Cited by 59
Wang, C. Y., Rademaker, M., Baker, C., & Foley, P. A. (2020) · Australasian Journal of Dermatology · doi:10.1111/ajd.13313 · Cited by 48
Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis
Rewerska, B., Sher, L., Alpizar, S., Pauser, S., Pulka, G., Mozaffarian, N., Salhi, Y., Martinet, C., Jabert, W., Gudi, G. S., et al. (2023) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2023.100195 · Cited by 63
Kratchmarov, R., Djeddi, S., Dunlap, G. S., He, W., Jia, X., Burk, C. M., Ryan, T., McGill, A., Allegretti, J. R., Kataru, R. P., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01803-2 · Cited by 55
Dupilumab in the treatment of moderate-to-severe atopic dermatitis
Kraft, M., & Worm, M. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1292134 · Cited by 52
Self-citationPatient Burden of Atopic Dermatitis
Sibbald, C. J., & Drucker, A. M. (2017) · Dermatologic Clinics · doi:10.1016/j.det.2017.02.004 · Cited by 53
Guidelines for the management of atopic dermatitis (eczema) for pharmacists
Wong, I. T. Y., Tsuyuki, R. T., Cresswell-Melville, A., Doiron, P., & Drucker, A. M. (2017) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163517710958 · Cited by 55
New and emerging targeted systemic therapies: a new era for atopic dermatitis
Lee, D. E., Clark, A. K., Tran, K. A., & Shi, V. Y. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1373736 · Cited by 52
“Dupilumab (DupixentR ) is a fully human monoclonal antibody that binds to the shared a-subunit of IL-4 and IL-13 receptors, thereby inhibiting their shared signaling pathway (51).”
BackgroundMethodResultInfluentialExtrafollicular IgD+ B cells generate IgE antibody secreting cells in the nasal mucosa
Corrado, A., Ramonell, R. P., Woodruff, M. C., Tipton, C. M., Wise, S. K., Levy, J. M., DelGaudio, J. M., Kuruvilla, M. E., Magliocca, K. R., Tomar, D., et al. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00410-w · Cited by 54
Selective IL-13 inhibitors for the treatment of atopic dermatitis
Gonçalves, F., Freitas, E., & Torres, T. R. (2021) · Drugs in Context · doi:10.7573/dic.2021-1-7 · Cited by 56
Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study
Numata, T., Araya, J., Miyagawa, H., Okuda, K., Takekoshi, D., Hashimoto, M., Minagawa, S., Ishikawa, T., Hara, H., & Kuwano, K. (2022) · Journal of Asthma and Allergy · doi:10.2147/jaa.s357548 · Cited by 47
Annoying Psoriasis and Atopic Dermatitis: A Narrative Review
Chen, W., Chen, S.-C., Hsu, S.-Y., Lin, Y.-A., Shih, C.-M., Huang, C., Wang, K.-H., & Lee, A.-W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094898 · Cited by 54
“safety profile when compared to a placebo in patients with moderate to severe AD [86].”
BackgroundMaintz, L., Bieber, T. R. M., Simpson, H. D., & Demessant‐Flavigny, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12060893 · Cited by 61
“Blocking the IL-4/IL-13 pathway shows efficacy for treating the inflammatory aspects of many, but not all, patients with moderate-to-severe AD, stressing the need for precision medicine with stratification by comorbidities and other phenotypic traits as well as the endotype [3,130].”
BackgroundSelf-citationRisks and safety of biologics: A practical guide for allergists
Sitek, A. N., Li, J. T., & Pongdee, T. (2023) · World Allergy Organization Journal · doi:10.1016/j.waojou.2022.100737 · Cited by 56
“In the SOLO 1 and SOLO 2 trials, conjunctivitis was reported in 3–5% of patients receiving dupilumab, compared to 1% of patients receiving placebo.(54) In the Liberty Ad Chronos Trial, the reported rate was higher for both groups, occurring in 14–23% of patients on dupilumab and 9% of patients receiving placebo.”
BackgroundResultThe evolving landscape of biologic therapies for atopic dermatitis: Present and future perspective
David, E., Ungar, B., Renert‐Yuval, Y., Facheris, P., DUCA, E. D., & Guttman‐Yassky, E. (2023) · Clinical & Experimental Allergy · doi:10.1111/cea.14263 · Cited by 52
Self-citationImmune Dysregulation in the Pathogenesis of Atopic Dermatitis
Gavrilova, T. (2018) · Dermatitis · doi:10.1097/der.0000000000000340 · Cited by 49
“Two phase 3 clinical trials demonstrated its efficacy in improving symptoms ofmoderate to severe AD in patients 18 years or older.(60) A clinical trial is currently underway studying its effects in pediatric patients.”
Katoh, N., Kataoka, Y., Saeki, H., Hide, M., Kabashima, K., Etoh, T., Igarashi, A., Imafuku, S., Kawashima, M., Ohtsuki, M., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18565 · Cited by 47
Self-citationLam, M., Zhu, J. W., Maqbool, T., Adam, G. P., Tadrous, M., Rochon, P. A., & Drucker, A. M. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.2940 · Cited by 47
Agache, I. O., Akdiş, C. A., Akdiş, M., Brockow, K., Chivato, T., Giacco, S. D., Eiwegger, T., Eyerich, K., Giménez‐Arnau, A. M., Gutermuth, J., et al. (2020) · Allergy · doi:10.1111/all.14690 · Cited by 56
Self-citationPaller, A. S., Beck, L. A., Blauvelt, A., Siegfried, E. C., Cork, M. J., Wollenberg, A., Chen, Z., Khokhar, F. A., Vakil, J., Zhang, A., et al. (2022) · Pediatric Dermatology · doi:10.1111/pde.14909 · Cited by 52
Self-citationEfficacy of biologics in atopic dermatitis
Wu, J., & Guttman-Yassky, E. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1722998 · Cited by 46
“In SOLO1 and SOLO2, adults with moderate-to-severe AD inadequately controlled on topical therapies were randomized to subcutaneous dupilumab 300 mg weekly, 300 mg every other week alternating with placebo (q2w), or placebo weekly (qw) [44].”
BackgroundSelf-citationWhat's new in the treatment of atopic dermatitis?
Dattola, A., Bennardo, L., Silvestri, M., & Nisticò, S. P. (2018) · Dermatologic Therapy · doi:10.1111/dth.12787 · Cited by 46
“…Baricitinib Guttman-Yassky et al. (2018) Oral 2 mg, 4 mg, placebo daily EASI-50: 61% (4 mg) versus 37% (placebo) those in the placebo groups in additional measures of clinical severity, including EASI-50, EASI-90, body-surface area affected, and scores like SCORAD and GISS (Simpson et al., 2016).”
BackgroundUpdate “Systemic treatment of atopic dermatitis” of the S2k‐guideline on atopic dermatitis
Werfel, T., Heratizadeh, A., Aberer, W., Ahrens, F., Augustin, M., Biedermann, T., Diepgen, T. L., Fölster‐Holst, R., Kahle, J., Kapp, A., et al. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14371 · Cited by 46
Self-citationOptimizing topical management of atopic dermatitis
Butala, S., & Paller, A. S. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.03.004 · Cited by 55
Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis
Tomomatsu, K., Yasuba, H., Ishiguro, T., Imokawa, S., Hara, J., Soeda, S., Harada, N., Tsurikisawa, N., Oda, N., Katoh, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-32246-8 · Cited by 51
Silverberg, J. I., Rosmarin, D. M., Chovatiya, R., Bieber, T. R. M., Schleicher, S., Beck, L. A., Gooderham, M., Chaudhry, S., Fanton, C. P., Yu, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53384-1 · Cited by 56
Self-citationEnglish version of clinical practice guidelines for the management of atopic dermatitis 2024
Saeki, H., Ohya, Y., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tanizaki, H., Tsunemi, Y., Nakahara, T., et al. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17544 · Cited by 59
Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis
Nakahara, T., Morimoto, H., Murakami, N., & Furue, M. (2017) · Pediatric Allergy and Immunology · doi:10.1111/pai.12842 · Cited by 48
A case of atopic eczema treated safely with dupilumab during pregnancy and lactation
Kage, P., Simon, J. C., & Treudler, R. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16235 · Cited by 46
Dupilumab-Associated Mucin Deficiency (DAMD)
Barnett, B. P., & Afshari, N. A. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.3.29 · Cited by 46
Ferrucci, S. M., Casazza, G., Angileri, L., Tavecchio, S., Germiniasi, F., Berti, E., Marzano, A. V., & Genovese, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030791 · Cited by 52
“Although the underlying mechanism of blepharoconjunctivitis in AD patients is still not completely elucidated, some authors have suggested that the blockade of IL-4 and IL-13 may increase the activity of specific ligands, such as OX40 ligand, involved in atopic keratoconjunctivitis [31].”
BackgroundA Practical Approach to Recalcitrant Face and Neck Dermatitis in Atopic Dermatitis
Jaros, J., Hendricks, A. J., Shi, V. Y., & Lio, P. (2020) · Dermatitis · doi:10.1097/der.0000000000000590 · Cited by 49
“Several trials have shown that dupilumab significantly improves skin lesion severity, symptoms, and health-related qualityof-life scores in patients with moderate to severe AD previously uncontrolled with topical agents.(8) Importantly, dupilumab has been shown to treat AD effectively everywhere on the body, including…”
BackgroundBoeri, M., Sutphin, J., Hauber, B., Cappelleri, J. C., Romero, W., & Bonaventura, M. D. (2020) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1832185 · Cited by 53
Mirza, F. N., Wang, A., Ramachandran, S. M., Damsky, W., & Cohen, J. M. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20064 · Cited by 46
Abdel-Mageed, H. M. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01642-z · Cited by 45
“SOLO 1 and SOLO 2 clinical studies involved enrolling individuals with moderate-to-severe atopic dermatitis whose condition was not well controlled by topical therapy in two randomized, placebo-controlled, phase 3 studies of the same design (Simpson et al. 2016).”
Medicinal potential of Panax ginseng and its ginsenosides in atopic dermatitis treatment
Lorz, L. R., Kim, M., & Cho, J. Y. (2019) · Journal of Ginseng Research · doi:10.1016/j.jgr.2018.12.012 · Cited by 45
“In addition, specific AD mediator’s inhibition treatments have been developed such as cyclosporine A [32] and azathioprine [33] (Tcell inhibitors), infliximab [34] (TNF-a inhibitor), omalizumab [35] (IgE inhibitor), mepolizumab (IL-5 inhibitor) [11], and dupilumab (IL-4 and IL-13 inhibitors) [36].”
BackgroundNovel Approaches in the Inhibition of IgE-Induced Mast Cell Reactivity in Food Allergy
Tontini, C., & Bulfone‐Paus, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.613461 · Cited by 51
Technological advancements in antibody-based therapeutics for treatment of diseases
Lu, R., Chiang, H.-L., Yuan, J. P., Wang, H.-H., Chen, C.-Y., Panda, S. S., Liang, K.-H., Peng, H., Ko, S.-H., Hsu, H.-J., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01190-2 · Cited by 68
Blauvelt, A., Rosmarin, D. M., Bieber, T. R. M., Simpson, E. L., Bagel, J., Worm, M., Deleuran, M. S., Katoh, N., Kawashima, M., Shumel, B. S., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17703 · Cited by 44
Self-citationT‐cell positioning by chemokines in autoimmune skin diseases
Richmond, J. M., Strassner, J. P., Essien, K. I., & Harris, J. E. (2019) · Immunological Reviews · doi:10.1111/imr.12762 · Cited by 53
Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology
Aoki, V., Lorenzini, D., Orfali, R. L., Zaniboni, M. C., de Oliveira, Z. N. P., Machado, M. C. R., Takaoka, R., Weber, M. B., Cestari, T. F., Gontijo, B., et al. (2019) · Anais Brasileiros de Dermatologia · doi:10.1590/abd1806-4841.2019940210 · Cited by 64
Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome
Sogkas, G., Hirsch, S., Dopfer‐Jablonka, A., Witte, T., Schmidt, R. E., & Atschekzei, F. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108452 · Cited by 45
Chiricozzi, A., Gori, N., Narcisi, A., Balato, A., Gambardella, A., Ortoncelli, M., Marzano, A. V., Balestri, R., Palazzo, G., Pellegrino, M., et al. (2022) · Drugs in R&D · doi:10.1007/s40268-022-00396-1 · Cited by 45
Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice
Schlösser, A. R., Shareef, M., Olydam, J. I., Nijsten, T. E. C., & Hijnen, D. (2023) · Clinical and Experimental Dermatology · doi:10.1093/ced/llad038 · Cited by 50
Simpson, E. L. (2017) · Dermatology and Therapy · doi:10.1007/s13555-017-0181-6 · Cited by 45
“Since trial designs were identical [3], we report EQ-5D results from both trials in a pooled analysis using censoring after rescue and last-observation-carried-forward.”
MethodResultInfluentialSelf-citation
Metadata
- Authors
- Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., Kingo, K., Worm, M., Poulin, Y., Wollenberg, A., Soo, Y., Graham, N. M. H., Pirozzi, G., Akinlade, B., Staudinger, H., Mastey, V., Eckert, L., Gadkari, A., Stahl, N., Yancopoulos, G. D., & Ardeleanu, M.
- Affiliations
- University of Bonn (DE)
- Northwestern University (US)
- ORCID
- Simpson, Eric L.
- Bieber, Thomas
- Beck, Lisa A.
- Blauvelt, Andrew
- Cork, Michael J.
- Silverberg, Jonathan I.
- Deleuran, Mette
- Kataoka, Yoko
- Lacour, Jean-Philippe
- Kingo, Külli
- Worm, Margitta
- Poulin, Yves
- Wollenberg, Andreas
- Soo, Yuhwen
- Graham, Neil M.H.
- Pirozzi, Gianluca
- Akinlade, Bolanle
- Staudinger, Heribert
- Eckert, Laurent
- Stahl, Neil
- Ardeleanu, Marius
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-15
- Volume
- 375
- Issue
- 24
- Pages
- 2335-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2524051065
- Cited by
- 2,110
- References
- 38
- Citations by year
- 2026: 183 · 2025: 219 · 2024: 227 · 2023: 239 · 2022: 218 · 2021: 238 · 2020: 244 · 2019: 236 · 2018: 160 · 2017: 130 · 2016: 8
- FWCI
- 211.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- Scopus (Elsevier) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- ab, atopic dermatitis, IL-4 receptor alpha, IL-13, IL-4, type 2 cytokines, monoclonal antibodies, subcutaneous administration, dosing frequency, Investigator's Global Assessment, Eczema Area and Severity Index, pruritus, injection site reactions, conjunctivitis, quality of life
- MeSH terms
- Adult, Anti-Inflammatory Agents, Antibodies, Monoclonal, Dermatitis, Atopic, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Nasopharyngitis, Pruritus, Quality of Life, Interleukin-4, Interleukin-13, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.